EVMN earnings date and last-quarter result: next report 2026-10-16, last quarter beat, P/E -4.77. Updated 2026-07-23.
Evommune (EVMN) Research Hub
Evommune (EVMN) trades on NYSE, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 5.13 USD (+0.59%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.77, market cap 0.16B. This hub links to the full technical, earnings and options research available for EVMN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NYSE, US |
| Last close | 5.13 USD (+0.59%) |
| 52-week range | 4.94 USD – 25.87 USD |
| Trend regime | Range |
| 14-day RSI | 23 (Oversold) |
| Trailing P/E | -4.77 |
| Market cap | 0.16B |
| Dividend yield | 0.00% |
| Next earnings | 2026-10-16 |
Available research for EVMN
Covered Call on EVMN: how it works, illustrative setup around the real 5.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on EVMN: how it works, illustrative setup around the real 5.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on EVMN: how it works, illustrative setup around the real 5.13 USD price, max profit/loss, breakeven and when to use it. Educational.
EVMN technical analysis: range, last 5.13 USD, RSI 23, 52w range 4.94 USD–25.87 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is EVMN in?
Evommune (EVMN) is classified under Healthcare (Biotechnology), listed on NYSE, US.
Is EVMN in an uptrend or downtrend?
As of 2026-10-26, EVMN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is EVMN's trailing P/E ratio?
EVMN's trailing P/E is -4.77, with a market cap of 0.16B. See the earnings research page for full valuation detail.
When does EVMN next report earnings?
EVMN is next scheduled to report earnings on 2026-10-16.